231 related articles for article (PubMed ID: 17204748)
1. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.
Dhalla AK; Santikul M; Smith M; Wong MY; Shryock JC; Belardinelli L
J Pharmacol Exp Ther; 2007 Apr; 321(1):327-33. PubMed ID: 17204748
[TBL] [Abstract][Full Text] [Related]
2. Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo.
Shearer J; Severson DL; Su L; Belardinelli L; Dhalla AK
J Pharmacol Exp Ther; 2009 Jan; 328(1):306-11. PubMed ID: 18952888
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats.
Dhalla AK; Santikul M; Chisholm JW; Belardinelli L; Reaven GM
Diabetes Obes Metab; 2009 Feb; 11(2):95-101. PubMed ID: 18494808
[TBL] [Abstract][Full Text] [Related]
4. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents.
Dhalla AK; Wong MY; Voshol PJ; Belardinelli L; Reaven GM
Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1358-63. PubMed ID: 17227958
[TBL] [Abstract][Full Text] [Related]
5. A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes.
Fatholahi M; Xiang Y; Wu Y; Li Y; Wu L; Dhalla AK; Belardinelli L; Shryock JC
J Pharmacol Exp Ther; 2006 May; 317(2):676-84. PubMed ID: 16410404
[TBL] [Abstract][Full Text] [Related]
6. N-[3-(R)-tetrahydrofuranyl]-6-aminopurine riboside, an A1 adenosine receptor agonist, antagonizes catecholamine-induced lipolysis without cardiovascular effects in awake rats.
Fraser H; Gao Z; Ozeck MJ; Belardinelli L
J Pharmacol Exp Ther; 2003 Apr; 305(1):225-31. PubMed ID: 12649373
[TBL] [Abstract][Full Text] [Related]
7. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridemic rats by the adenosine receptor agonist phenylisopropyladenosine.
Hoffman BB; Dall'Aglio E; Hollenbeck C; Chang H; Reaven GM
J Pharmacol Exp Ther; 1986 Dec; 239(3):715-8. PubMed ID: 3795036
[TBL] [Abstract][Full Text] [Related]
8. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats.
van Schaick EA; Tukker HE; Roelen HC; IJzerman AP; Danhof M
Br J Pharmacol; 1998 Jun; 124(3):607-18. PubMed ID: 9647488
[TBL] [Abstract][Full Text] [Related]
9. Modulation of insulin release by adenosine A1 receptor agonists and antagonists in INS-1 cells: the possible contribution of 86Rb+ efflux and 45Ca2+ uptake.
Töpfer M; Burbiel CE; Müller CE; Knittel J; Verspohl EJ
Cell Biochem Funct; 2008 Dec; 26(8):833-43. PubMed ID: 18979526
[TBL] [Abstract][Full Text] [Related]
10. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans.
Rigazio S; Lehto HR; Tuunanen H; Någren K; Kankaanpaa M; Simi C; Borra R; Naum AG; Parkkola R; Knuuti J; Nuutila P; Iozzo P
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E413-9. PubMed ID: 18505832
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin.
Johansson SM; Lindgren E; Yang JN; Herling AW; Fredholm BB
Eur J Pharmacol; 2008 Nov; 597(1-3):92-101. PubMed ID: 18789919
[TBL] [Abstract][Full Text] [Related]
12. Glucose-dependent insulin modulation of oscillatory lipolysis in perifused rat adipocytes.
Getty-Kaushik L; Richard AM; Corkey BE
Obes Res; 2005 Dec; 13(12):2058-65. PubMed ID: 16421338
[TBL] [Abstract][Full Text] [Related]
13. Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid.
Johansson SM; Yang JN; Lindgren E; Fredholm BB
Acta Physiol (Oxf); 2007 May; 190(1):87-96. PubMed ID: 17428236
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action.
van Schaick EA; Zuideveld KP; Tukker HE; Langemeijer MW; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1998 Oct; 287(1):21-30. PubMed ID: 9765317
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.
Van der Graaf PH; Van Schaick EA; Visser SA; De Greef HJ; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1999 Aug; 290(2):702-9. PubMed ID: 10411581
[TBL] [Abstract][Full Text] [Related]
16. A1 adenosine receptor: role in diabetes and obesity.
Dhalla AK; Chisholm JW; Reaven GM; Belardinelli L
Handb Exp Pharmacol; 2009; (193):271-95. PubMed ID: 19639285
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and antilipolytic effects of the adenosine agonist GR79236.
Merkel LA; Hawkins ED; Colussi DJ; Greenland BD; Smits GJ; Perrone MH; Cox BF
Pharmacology; 1995 Oct; 51(4):224-36. PubMed ID: 8577816
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats.
Cox BF; Clark KL; Perrone MH; Welzel GE; Greenland BD; Colussi DJ; Merkel LA
J Cardiovasc Pharmacol; 1997 Mar; 29(3):417-26. PubMed ID: 9125682
[TBL] [Abstract][Full Text] [Related]
19. A1 adenosine receptor antagonists, agonists, and allosteric enhancers.
Kiesman WF; Elzein E; Zablocki J
Handb Exp Pharmacol; 2009; (193):25-58. PubMed ID: 19639278
[TBL] [Abstract][Full Text] [Related]
20. Acute metabolic effects of clonidine and adenosine in man.
Swislocki AL; Vestal RE; Reaven GM; Hoffman BB
Horm Metab Res; 1993 Feb; 25(2):90-5. PubMed ID: 8458615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
